Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck zepatier (elbasvir and grazoprevir — HCV, legacy) — U.S. reported growth YoY (%) (%)
Form 8-K Table 3a / 3b Product Sales
Latest, Q3 2020
-76.0%
Period ended Sep 30, 2020
Change on a year earlier
-106.0 pts
30.0% in Q3 2019
History
7 quarters
Since Q4 2017
Sources
7
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zepatier (elbasvir and grazoprevir — HCV, legacy) — U.S. reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2020 | Sep 30, 2020 | -76.0% | -106.0 pts | Form 8-K (tm2032785d1_ex99-1.htm, filed 2020-10-27) ↗ |
| Q2 2020 | Jun 30, 2020 | -62.0% | – | Form 8-K (tm2026006d1_ex99-1.htm, filed 2020-07-31) ↗ |
| Q1 2020 | Mar 31, 2020 | -46.0% | – | Form 8-K (tm2016917d1_ex99-1.htm, filed 2020-04-28) ↗ |
| Q3 2019 | Sep 30, 2019 | 30.0% | +122.0 pts | Form 8-K (tm1921023d1_ex99-1.htm, filed 2019-10-29) ↗ |
| Q3 2018 | Sep 30, 2018 | -92.0% | – | Form 8-K (a18-37128_1ex99d1.htm, filed 2018-10-25) ↗ |
| Q2 2018 | Jun 30, 2018 | -104.0% | – | Form 8-K (a18-17779_1ex99d1.htm, filed 2018-07-27) ↗ |
| Q4 2017 | Dec 31, 2017 | -51.0% | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Cite this data
StockData. (2026). Merck Zepatier (elbasvir and grazoprevir — HCV, legacy) — U.S. reported growth YoY (%) (%), quarterly Q4 2017–Q3 2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_zepatier_us_nom_yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.